REC announces Rs 4.60 interim dividend and proposes Rs 2.60 final dividend for FY25
REC has declared its 1st interim dividend of ₹4.60 per share for FY26. The record date for eligibility is August 1, 2025, and payment will be made by August 21, 2025.
Additionally, the company has proposed a final dividend of ₹2.60 per share for FY25, subject to shareholder approval at the upcoming AGM. The record date for this final dividend is set as August 14, 2025, with payment to follow within 30 days post-approval.
Total dividend payout (interim + proposed final): ₹7.20 per share
REC Limited also reported a consolidated net profit of Rs 4,465.71 crore for the quarter ended June 30, 2025 (Q1 FY26), marking a 29% year-on-year (YoY) rise compared to Rs 3,460.19 crore in the same quarter last year.
The company's total revenue from operations stood at Rs 14,737.45 crore, reflecting a 13% YoY growth from Rs 13,078.66 crore in Q1 FY25.
Total income, including other income, was reported at Rs 14,823.98 crore in Q1 FY26, up from Rs 13,092.44 crore a year ago. Profit before tax for the quarter stood at Rs 5,666.41 crore, compared to Rs 4,349.23 crore in the corresponding quarter of the previous year.
REC incurred total expenses of Rs 9,157.57 crore during the reporting quarter, slightly up from Rs 8,743.22 crore in Q1 FY25. Finance costs stood at Rs 8,934.18 crore for the quarter.
Ahmedabad Plane Crash
Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
ED arrests Ex-Axis Mutual Fund chief dealer Viresh Joshi in over Rs 200 crore front-running case
By Aditya Bhagchandani Published on August 3, 2025, 16:58 IST In a major crackdown on the Axis Mutual Fund front-running scandal, the Enforcement Directorate (ED) has arrested Viresh Gangaram Joshi, the former Chief Dealer of Axis Mutual Fund, under the Prevention of Money Laundering Act (PMLA), 2002. The arrest took place on August 2, 2025, and Joshi has been remanded to ED custody until August 8 for further investigation. The ED conducted search operations on August 1 and 2 across multiple locations including Delhi, Mumbai, Gurugram, Ludhiana, Ahmedabad, Bhavnagar, Bhuj, and Kolkata. These operations stem from an FIR filed by Mumbai Police in December 2024, which alleged that Joshi and others used confidential information about Axis Mutual Fund trades between 2018 and 2021 to execute personal trades ahead of client orders—a practice known as front-running. The investigation has uncovered that Joshi used a trading terminal in Dubai and multiple mule trading accounts to carry out these illicit trades. Several traders and brokers are also under the scanner for exploiting advance trade inputs to generate illegal profits. So far, the ED has identified proceeds of crime worth over Rs 200 crore, a figure that may increase as the probe progresses. As part of the operation, the ED has frozen assets—including shares, mutual fund holdings, and bank balances—worth Rs 17.4 crore. The proceeds were allegedly routed through shell companies and bank accounts linked to the accused and their family members. The ED emphasised that front-running erodes investor trust and undermines market integrity. Axis Mutual Fund currently manages assets worth over Rs 2 lakh crore. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Yahoo
a day ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Price Surges 9% Over Past Month
Recursion Pharmaceuticals experienced a price increase of 9% over the past month, positioning it against the backdrop of a broader market decline driven by geopolitical tensions and weak jobs data. Despite these broader market headwinds, which saw significant tech stock declines due to tariff concerns and disappointing economic indicators, Recursion managed to outperform. The company's stock movement appeared isolated from these wider trends, which implies internal factors or developments might have played a part, although specific catalysts weren't highlighted during this period. This performance is noteworthy given the current market's overall downward trend of 2.7%. We've identified 3 possible red flags for Recursion Pharmaceuticals (1 is potentially serious) that you should be aware of. AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. Recursion Pharmaceuticals' recent 9% monthly share price increase amidst broader market declines may suggest that internal developments, rather than external factors, are influencing investor sentiment. Over the past year, however, the company's total shareholder return was a decline of 19.09%, highlighting a contrast to the short-term positive movement. Comparatively, RXRX underperformed the US Biotechs industry, which saw an 8.4% decline over the same period, and also lagged behind the US market return of 17.7%. The heightened interest in the stock could be linked to enthusiasm around its AI-driven drug discovery programs, including REC-617 and REC-994 trials, which suggest potential future revenue growth. Yet, Recursion's lack of profitability and reliance on successful trial outcomes may introduce uncertainty into earnings forecasts. The company's expected revenue growth of 39.9% annually for the next three years could be influenced by the new developments and partnerships, possibly providing support to the optimistic forecasts. The current share price of US$5.68 remains below the consensus analyst price target of US$7.14, indicating a potential upside of 25.7%. This price target reflects expectations of significant future revenue and earnings improvements. However, analysts' forecasts include assumptions such as increased profit margins and successful translation of ongoing projects into commercial revenues, underscoring the importance of navigating the risks and uncertainties outlined in their analysis. Investors may need to weigh these factors carefully when considering the company's ability to meet future targets. Evaluate Recursion Pharmaceuticals' prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include RXRX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Business Upturn
a day ago
- Business Upturn
SML Isuzu appoints Vinod Kumar Sahay as Executive Chairman, effective August 3
By Aman Shukla Published on August 2, 2025, 17:11 IST SML Isuzu made several key announcements after its Board meeting held on August 2, 2025. Vinod Kumar Sahay has been appointed as the new Executive Chairman from August 3, 2025, taking over from Chandra Shekhar Verma, who will continue on the Board as an Independent Director. The company also announced changes in its finance leadership. Rakesh Bhalla will step down as CFO on September 30, 2025, and will move into an advisory role. Pushkar Patwardhan has been named CFO (Designate) effective immediately and will take full charge from October 1, 2025. Ritesh Agrawal has joined as the new Chief Operating Officer. With this new structure, Sandeep Chandna and Vikas Sharma will no longer be designated Senior Management Personnel but will remain with the company. Additionally, SML Isuzu's current statutory auditor, Walker Chandiok & Co LLP, has resigned citing independence concerns due to non-audit services provided to the holding company. In their place, B S R & Co. LLP has been appointed as the new statutory auditor effective August 2, 2025, subject to shareholder approval for a five-year term starting from the next AGM. These changes reflect a strategic shift as the company strengthens its leadership team and governance practices. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
